{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:08:16Z","timestamp":1784282896943,"version":"3.55.0"},"reference-count":72,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit in which Cutibacterium acnes plays an important role in disease pathogenesis. Rising antimicrobial resistance has intensified interest in selective antimicrobial strategies for acne vulgaris. Bacteriophage-derived endolysins may offer targeted antibacterial activity while potentially sparing the skin microbiota. This scoping review aimed to map current evidence regarding endolysins targeting C. acnes and to evaluate their antibacterial activity, selectivity, safety, formulation challenges, and translational potential. Methods: This scoping review was conducted in accordance with PRISMA-ScR guidelines. Searches on PubMed, Scopus, Embase, Web of Science, and Google Scholar were performed in February 2026. Experimental studies, academic theses, and patent documents investigating phage-derived endolysins active against C. acnes were included and narratively synthesised. Results: Five peer-reviewed studies, three academic theses, and seven patent documents were included. Most available evidence originated from in vitro studies, with only one short-term clinical investigation identified. Endolysins and engineered derivatives demonstrated rapid bactericidal activity against C. acnes, including multidrug-resistant isolates, while several constructs exhibited minimal activity against selected commensal skin bacteria. Lysin-derived peptides retained activity under physiologically relevant pH and temperature conditions and in the presence of retinoic acid. Major translational challenges included limited stability of enzyme formulations, insufficient pilosebaceous unit penetration data, lack of anti-biofilm evidence and unstandardised microbiome assessment methods. Conclusions: Phage-derived endolysins represent a promising targeted therapeutic strategy for acne vulgaris. However, current evidence remains predominantly preclinical, and substantial translational barriers related to delivery, stability, safety, anti-biofilm efficacy, microbiome homeostasis, and clinical validation must be addressed before routine dermatological application.<\/jats:p>","DOI":"10.3390\/antibiotics15070697","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:00:52Z","timestamp":1784278852000},"page":"697","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phage-Derived Endolysins Targeting Cutibacterium acnes: A Scoping Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7206-9907","authenticated-orcid":false,"given":"Magdalena","family":"So\u0142tys","sequence":"first","affiliation":[{"name":"Students\u2019 Scientific Association of Cosmetology, Department of Cosmetology and Aesthetic Dermatology, Faculty of Pharmacy, Medical University of Lodz, Muszy\u0144skiego 1, 91-151 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8443-0137","authenticated-orcid":false,"given":"Rafa\u0142","family":"Kuczma","sequence":"additional","affiliation":[{"name":"Students\u2019 Scientific Association of Clinical Microbiology, Department of Microbiology, Faculty of Medicine, Wroclaw Medical University, Cha\u0142ubi\u0144skiego 4, 50-368 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9889-4265","authenticated-orcid":false,"given":"Katarzyna","family":"Jermakow","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, Wroclaw Medical University, Cha\u0142ubi\u0144skiego 4, 50-368 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5457-2528","authenticated-orcid":false,"given":"Anna","family":"Erkiert-Polguj","sequence":"additional","affiliation":[{"name":"Department of Cosmetology and Aesthetic Dermatology, Faculty of Pharmacy, Medical University of Lodz, Muszy\u0144skiego 1, 91-151 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"ref_1","first-page":"101578","article-title":"Acne Vulgaris: A Review of the Pathophysiology, Treatment, and Recent Nanotechnology Based Advances","volume":"36","author":"Vasam","year":"2023","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10096-024-04984-8","article-title":"Acne Vulgaris: Advances in Pathogenesis and Prevention Strategies","volume":"44","author":"Xu","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9910076","DOI":"10.1155\/drp\/9910076","article-title":"The Mechanism and Research Progress of Skin Microbiota in Pathogenesis of Acne","volume":"2025","author":"Li","year":"2025","journal-title":"Dermatol. Res. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"van Steensel, M.A.M. (2026). The Evolving Microbial Paradigm in Acne. Biomolecules, 16.","DOI":"10.3390\/biom16030430"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40257-018-00417-3","article-title":"Acne, the Skin Microbiome, and Antibiotic Treatment","volume":"20","author":"Xu","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jdv.15043","article-title":"Cutibacterium Acnes (Propionibacterium Acnes) and Acne Vulgaris: A Brief Look at the Latest Updates","volume":"32","author":"Corvec","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mayslich, C., Grange, P.A., and Dupin, N. (2021). Cutibacterium Acnes as an Opportunistic Pathogen: An Update of Its Virulence-Associated Factors. Microorganisms, 9.","DOI":"10.3390\/microorganisms9020303"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100063","DOI":"10.1016\/j.bioflm.2021.100063","article-title":"The Role of Biofilm Formation in the Pathogenesis and Antimicrobial Susceptibility of Cutibacterium Acnes","volume":"4","author":"Coenye","year":"2022","journal-title":"Biofilm"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1006.e1","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of Care for the Management of Acne Vulgaris","volume":"90","author":"Reynolds","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","unstructured":"Nast, A., Al Wattar, B., Beylot Barry, M., Br\u00fcggemann, H., Bukvi\u0107 Mokos, Z., Caruana, D.M., Degitz, K., Dessinioti, C., Dr\u00e9no, B., and Driessen, R.J.B. (2026, April 02). EuroGuiDerm Evidence-Based Guideline for the Treatment of Acne\u2014Long Version (ICD L70.0, L70.1). Update 2025. Available online: https:\/\/www.guidelines.edf.one."},{"key":"ref_11","first-page":"21","article-title":"Optimal Use Recommendations and Stewardship Principles with Oral Antibiotics in Acne Vulgaris Management: An Expert Consensus Panel","volume":"18","author":"Rosenberg","year":"2025","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zhu, C., Wei, B., Li, Y., and Wang, C. (2025). Antibiotic Resistance Rates in Cutibacterium Acnes Isolated from Patients with Acne Vulgaris: A Systematic Review and Meta-Analysis. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1565111"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jgar.2024.07.005","article-title":"Prevalence of Antibiotic-Resistant Cutibacterium Acnes (Formerly Propionibacterium Acnes) Isolates, a Systematic Review and Meta-Analysis","volume":"39","author":"Beig","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_14","first-page":"429","article-title":"Antibiotics and Antimicrobial Resistance in Acne: Epidemiological Trends and Clinical Practice Considerations","volume":"95","author":"Dessinioti","year":"2022","journal-title":"Yale J. Biol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0019-5154.174025","article-title":"Cross-Sectional Pilot Study of Antibiotic Resistance in Propionibacterium Acnes Strains in Indian Acne Patients Using 16S-RNA Polymerase Chain Reaction: A Comparison Among Treatment Modalities Including Antibiotics, Benzoyl Peroxide, and Isotretinoin","volume":"61","author":"Sardana","year":"2016","journal-title":"Indian J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13555-023-01079-8","article-title":"The Microbiome and Acne: Perspectives for Treatment","volume":"14","author":"Dessinioti","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Smythe, P., and Wilkinson, H.N. (2023). The Skin Microbiome: Current Landscape and Future Opportunities. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043950"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Nied\u017awiedzka, A., Micallef, M.P., Biazzo, M., and Podrini, C. (2024). The Role of the Skin Microbiome in Acne: Challenges and Future Therapeutic Opportunities. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252111422"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nicholas-Haizelden, K., Murphy, B., Hoptroff, M., and Horsburgh, M.J. (2023). Bioprospecting the Skin Microbiome: Advances in Therapeutics and Personal Care Products. Microorganisms, 11.","DOI":"10.3390\/microorganisms11081899"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12929-023-00919-1","article-title":"Therapeutic Potential of Bacteriophage Endolysins for Infections Caused by Gram-Positive Bacteria","volume":"30","author":"Liu","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2509038","DOI":"10.4014\/jmb.2509.09038","article-title":"Substrate Specificity and Immunological Implications of Cutibacterium Acnes Phage Endolysins","volume":"36","author":"Bashir","year":"2026","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16430","DOI":"10.1038\/s41598-023-43559-z","article-title":"Expression of a Recombinant Endolysin from Bacteriophage CAP 10-3 with Lytic Activity against Cutibacterium Acnes","volume":"13","author":"Kim","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Varotsou, C., Premetis, G.E., and Labrou, N.E. (2023). Characterization and Engineering Studies of a New Endolysin from the Propionibacterium acnes Bacteriophage PAC1 for the Development of a Broad-Spectrum Artilysin with Altered Specificity. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108523"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e01168-25","DOI":"10.1128\/aem.01168-25","article-title":"Comparative Antibacterial Activity of N-Terminal and C-Terminal Domains of a Recombinant Endolysin against Cutibacterium Acnes","volume":"91","author":"Lee","year":"2025","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4103\/MJBL.MJBL_91_23","article-title":"Novel Bacteriophage Cocktail, Endolysin-Hydroxyethyl Cellulose Gel, and Mixture Gel Therapy for Acne Vulgaris Caused by Multidrug Resistant Propionibacterium (Cutibacterium) Acnes","volume":"22","author":"Hussain","year":"2025","journal-title":"Med. J. Babylon"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sela, U., Heselpoth, R.D., and Fischetti, V.A. (2025). Engineered Lysin-Derived Peptide as a Potent Antimicrobial for Acne Vulgaris. Antibiotics, 14.","DOI":"10.3390\/antibiotics14040344"},{"key":"ref_27","unstructured":"Collins, K.M. (2023). Production and Characterization of a Phage Endolysin with Putative Antimicrobial Activity Against Cutibacterium Acnes. [Master\u2019s Thesis, Eastern Washington University]. Available online: https:\/\/dc.ewu.edu\/theses\/839\/."},{"key":"ref_28","unstructured":"Kelley, M.C. (2023). Development of Recombinant Endolysins against Gram-Negative and Gram-Positive Bacteria. [Master\u2019s Thesis, California State Polytechnic University]. Available online: https:\/\/scholarworks.calstate.edu\/concern\/theses\/5x21tp56h."},{"key":"ref_29","unstructured":"Murray, E. (2024). Therapeutic and Diagnostic Potential of Endolysins Targeting Gram-Positive Pathogens. [Ph.D. Thesis, University College Cork]. Available online: https:\/\/cora.ucc.ie\/items\/C3eb58c5-D4bc-46cb-8370-C9c28a99bc16."},{"key":"ref_30","unstructured":"Wuhan Lysigen Bio-Tech Company Limited (2025). Bacteriophage Lysine, Chimera Thereof and Application Thereof. (20250288652A1), U.S. Patent."},{"key":"ref_31","unstructured":"Integrated Pharma Services LLC (2024). Device and Methods for Acne Therapeutics: Antibacterial Bacteriophages and Engineered Lysins. (20240277791A1), U.S. Patent."},{"key":"ref_32","unstructured":"Lysando, A.G. (2012). Antimicrobial Agents. (20120195872A1), U.S. Patent."},{"key":"ref_33","unstructured":"Conopco Inc (2023). An Effective Anti-Acne Personal Care Composition. (20230106068A1), U.S. Patent."},{"key":"ref_34","unstructured":"Conopco Inc (2021). An Antimicrobial Composition for Selectively Inhibiting Growth of P. Acnes Bacteria. (20210386835A1), U.S. Patent."},{"key":"ref_35","unstructured":"University of Maryland College Park (2026). Method of Treating Infections by Bacteriolytic Enzymes and Manufacture Thereof. (12516309B2), U.S. Patent."},{"key":"ref_36","unstructured":"Topaz Biosciences Inc (2025). Cell Wall Hydrolases Targeting C. acnes. (12312617B2), U.S. Patent."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Santiago-Rodriguez, T.M., Le Fran\u00e7ois, B., Macklaim, J.M., Doukhanine, E., and Hollister, E.B. (2023). The Skin Microbiome: Current Techniques, Challenges, and Future Directions. Microorganisms, 11.","DOI":"10.3390\/microorganisms11051222"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2147\/JIR.S441100","article-title":"Microbiome: Role in Inflammatory Skin Diseases","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jdv.20332","article-title":"Acne and the Cutaneous Microbiome: A Systematic Review of Mechanisms and Implications for Treatments","volume":"39","author":"Podwojniak","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"21104","DOI":"10.1038\/s41598-022-25436-3","article-title":"Skin Dysbiosis and Cutibacterium Acnes Biofilm in Inflammatory Acne Lesions of Adolescents","volume":"12","author":"Cavallo","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/12034754211037994","article-title":"The Impact of Acne Treatment on Skin Bacterial Microbiota: A Systematic Review","volume":"26","author":"Lam","year":"2022","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e00165-25","DOI":"10.1128\/jb.00165-25","article-title":"Staphylococcus Epidermidis\u2014Key to Understanding Biofilms, Commensalism, and More","volume":"207","author":"Cheung","year":"2025","journal-title":"J. Bacteriol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e00279-12","DOI":"10.1128\/mBio.00279-12","article-title":"Propionibacterium Acnes Bacteriophages Display Limited Genetic Diversity and Broad Killing Activity against Bacterial Skin Isolates","volume":"3","author":"Marinelli","year":"2012","journal-title":"mBio"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13555-018-0275-9","article-title":"Propionibacterium (Cutibacterium) Acnes Bacteriophage Therapy in Acne: Current Evidence and Future Perspectives","volume":"9","author":"Castillo","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/ismej.2015.47","article-title":"The Diversity and Host Interactions of Propionibacterium Acnes Bacteriophages on Human Skin","volume":"9","author":"Liu","year":"2015","journal-title":"ISME J."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Nguyen, P.-D., Nakanishi, K., Nguyen, H.P.-K., Nguyen, H.V., Kitao, M., Yoshimoto, M., and Kamei, K. (2025). Characterisation of the Novel Cutibacterium acnes Phage KIT09 and First Report of CRISPR-Cas-Independent Bacteriophage Resistance in Phylotype IA1. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262412166"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Qian, H., and Zheng, Y. (2026). Phage endolysins as alternative antimicrobials: Mechanisms, clinical progress, and emerging resistance frameworks. Front. Microbiol., 17.","DOI":"10.3389\/fmicb.2026.1762768"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e70280","DOI":"10.1002\/mco2.70280","article-title":"Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside","volume":"6","author":"Mohebi","year":"2025","journal-title":"MedComm"},{"key":"ref_49","first-page":"54122s4","article-title":"Pathophysiologic Targets of Acne Treatment","volume":"23","author":"Graber","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Uru\u00e9n, C., Chopo-Escuin, G., Tommassen, J., Mainar-Jaime, R.C., and Arenas, J. (2021). Biofilms as Promoters of Bacterial Antibiotic Resistance and Tolerance. Antibiotics, 10.","DOI":"10.3390\/antibiotics10010003"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Gannesen, A.V., Zdorovenko, E.L., Botchkova, E.A., Hardouin, J., Massier, S., Kopitsyn, D.S., Gorbachevskii, M.V., Kadykova, A.A., Shashkov, A.S., and Zhurina, M.V. (2019). Composition of the Biofilm Matrix of Cutibacterium Acnes Acneic Strain RT5. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.01284"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e12576","DOI":"10.1111\/dth.12576","article-title":"The Role of Zinc in the Treatment of Acne: A Review of the Literature","volume":"31","author":"Cervantes","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Khan, F.M., Rasheed, F., Yang, Y., Liu, B., and Zhang, R. (2024). Endolysins: A New Antimicrobial Agent against Antimicrobial Resistance. Strategies and Opportunities in Overcoming the Challenges of Endolysins against Gram-Negative Bacteria. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1385261"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1007\/s12602-025-10853-3","article-title":"Designing the Next Generation of Endolysins: A Triple Strategy Integrating Bioinformatics Mining, Engineering Modification and Encapsulation Formulation","volume":"18","author":"Zhang","year":"2026","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.12788\/cutis.0844","article-title":"From Breakouts to Bargains: Strategies for Patient-Centered, Cost-effective Acne Care","volume":"112","author":"Shields","year":"2023","journal-title":"Cutis"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1042\/EBC20240019","article-title":"A comparative guide to expression systems for phage lysin production","volume":"68","author":"Cremelie","year":"2024","journal-title":"Essays Biochem."},{"key":"ref_57","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2003). ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A(R2), ICH. Current Step 4 Version."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.jid.2025.03.045","article-title":"Immune Activation and Glycolytic Responses to Cutibacterium acnes Cell Wall Polysaccharides","volume":"145","author":"Qin","year":"2025","journal-title":"J. Investig. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Mayslich, C., Grange, P.A., Castela, M., Marcelin, A.G., Calvez, V., and Dupin, N. (2022). Characterization of a Cutibacterium acnes Camp Factor 1-Related Peptide as a New TLR-2 Modulator in In Vitro and Ex Vivo Models of Inflammation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23095065"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/bs.apcsb.2025.09.001","article-title":"Bacteriophage Endolysins: A Promising Therapeutic Strategy against Drug- Resistant Staphylococcus Aureus","volume":"149","author":"Rajesh","year":"2026","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_61","unstructured":"World Health Organization (2017). Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics, WHO."},{"key":"ref_62","unstructured":"CDC (2019). Antibiotic Resistance Threats in the United States, 2019."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/1040841X.2020.1809346","article-title":"Advanced Engineering of Third-Generation Lysins and Formulation Strategies for Clinical Applications","volume":"46","author":"Paeshuyse","year":"2020","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Cheng, M., Zhan, L., Zhang, H., Li, X., Wang, Y., Xia, F., Wang, B., Cai, R., Guo, Z., and Zhang, Y. (2018). An Ointment Consisting of the Phage Lysin LysGH15 and Apigenin for Decolonization of Methicillin-Resistant Staphylococcus Aureus from Skin Wounds. Viruses, 10.","DOI":"10.3390\/v10050244"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s13555-017-0185-2","article-title":"Why Topical Retinoids Are Mainstay of Therapy for Acne","volume":"7","author":"Leyden","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/09546634.2016.1214234","article-title":"The Extinction of Topical Erythromycin Therapy for Acne Vulgaris and Concern for the Future of Topical Clindamycin","volume":"28","author":"Austin","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-019-00423-z","article-title":"Topical Retinoids in Acne Vulgaris: A Systematic Review","volume":"20","author":"Kolli","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Rahman, M.U., Wang, W., Sun, Q., Shah, J.A., Li, C., Sun, Y., Li, Y., Zhang, B., Chen, W., and Wang, S. (2021). Endolysin, a Promising Solution against Antimicrobial Resistance. Antibiotics, 10.","DOI":"10.3390\/antibiotics10111277"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000473872","article-title":"Successful Treatment of Chronic Staphylococcus Aureus-Related Dermatoses with the Topical Endolysin Staphefekt SA.100: A Report of 3 Cases","volume":"9","author":"Pasmans","year":"2017","journal-title":"Case Rep. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jaci.2019.05.020","article-title":"Endolysin Treatment against Staphylococcus Aureus in Adults with Atopic Dermatitis: A Randomized Controlled Trial","volume":"144","author":"Schuren","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Gontijo, M.T.P., Jorge, G.P., and Brocchi, M. (2021). Current Status of Endolysin-Based Treatments against Gram-Negative Bacteria. Antibiotics, 10.","DOI":"10.3390\/antibiotics10101143"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Aitken, M., Abeysekera, G., Billington, C., and Dobson, R.C.J. (2025). Recent Advances in Endolysin Engineering. Antibiotics, 14.","DOI":"10.3390\/antibiotics14121285"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/7\/697\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:41:34Z","timestamp":1784281294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/7\/697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":72,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["antibiotics15070697"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15070697","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}